[go: up one dir, main page]

WO2001060975A3 - Methodologies de disruption genique destinees a la decouverte de medicaments cibles - Google Patents

Methodologies de disruption genique destinees a la decouverte de medicaments cibles Download PDF

Info

Publication number
WO2001060975A3
WO2001060975A3 PCT/US2001/005551 US0105551W WO0160975A3 WO 2001060975 A3 WO2001060975 A3 WO 2001060975A3 US 0105551 W US0105551 W US 0105551W WO 0160975 A3 WO0160975 A3 WO 0160975A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
essential
gene
allele
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/005551
Other languages
English (en)
Other versions
WO2001060975A2 (fr
Inventor
Terry Roemer
Bo Jiang
Charles Boone
Howard Bussey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elitra Pharmaceuticals Inc
Original Assignee
Elitra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elitra Pharmaceuticals Inc filed Critical Elitra Pharmaceuticals Inc
Priority to JP2001560347A priority Critical patent/JP2003523197A/ja
Priority to CA002398861A priority patent/CA2398861A1/fr
Priority to EP01916144A priority patent/EP1292668A2/fr
Priority to KR1020027010815A priority patent/KR20020097180A/ko
Priority to NZ521037A priority patent/NZ521037A/en
Priority to AU2001243204A priority patent/AU2001243204A1/en
Publication of WO2001060975A2 publication Critical patent/WO2001060975A2/fr
Publication of WO2001060975A3 publication Critical patent/WO2001060975A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et compositions permettant de déterminer de manière expérimentale si un quelconque gène du génome d'un organisme pathogène diploïde est essentiel et s'il est nécessaire à la virulence ou au pouvoir pathogène. Ces procédés consistent à construire des mutants génétiques dans lesquels un allèle d'un gène spécifique est inactivé tandis que l'autre allèle du gène est placé dans des conditions d'éventuelle expression. L'identification de gènes essentiels et de gènes critiques quant au développement d'infections virulentes constitue une base de développement du criblage de nouveaux médicaments dirigés contre ces organismes pathogènes. L'invention concerne encore des gènes ∫i⊃Candida albicans∫/i⊃ qui se sont révélés être essentiels dans le criblage de médicaments et constituent des cibles potentielles à cette fin. On peut utiliser la séquence nucléotidique de ces gènes cibles à des fins de découverte de médicaments, telle que l'expression de la protéine de recombinaison, le dosage d'hybridation et la construction d'ensembles d'acides nucléiques. L'invention concerne enfin l'utilisation de protéines, codées par les gènes essentiels, et de cellules modifiées génétiquement et comprenant des allèles modifiés de gènes essentiels, dans divers procédés de criblage.
PCT/US2001/005551 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles Ceased WO2001060975A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001560347A JP2003523197A (ja) 2000-02-18 2001-02-20 薬物標的探索のための遺伝子破壊法
CA002398861A CA2398861A1 (fr) 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles
EP01916144A EP1292668A2 (fr) 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles
KR1020027010815A KR20020097180A (ko) 2000-02-18 2001-02-20 약물 표적 발견을 위한 유전자 분열 방법
NZ521037A NZ521037A (en) 2000-02-18 2001-02-20 Gene disruption methodologies for drug target discovery
AU2001243204A AU2001243204A1 (en) 2000-02-18 2001-02-20 Gene disruption methodologies for drug target discovery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18353400P 2000-02-18 2000-02-18
US60/183,534 2000-02-18

Publications (2)

Publication Number Publication Date
WO2001060975A2 WO2001060975A2 (fr) 2001-08-23
WO2001060975A3 true WO2001060975A3 (fr) 2002-04-25

Family

ID=22673211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005551 Ceased WO2001060975A2 (fr) 2000-02-18 2001-02-20 Methodologies de disruption genique destinees a la decouverte de medicaments cibles

Country Status (7)

Country Link
EP (1) EP1292668A2 (fr)
JP (1) JP2003523197A (fr)
KR (1) KR20020097180A (fr)
AU (1) AU2001243204A1 (fr)
CA (1) CA2398861A1 (fr)
NZ (1) NZ521037A (fr)
WO (1) WO2001060975A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
AU2002355155A1 (en) * 2001-07-24 2003-02-17 Affinium Pharmaceuticals Inc. Methods for gene disruption and uses thereof
WO2003091418A2 (fr) 2002-04-26 2003-11-06 Bristol-Myers Squibb Company Nouveaux polynucleotides fongiques essentiels, polypeptides et techniques d'utilisation
GB0228704D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228697D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228702D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228694D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel threapeutic target
EP1466974A1 (fr) * 2003-04-11 2004-10-13 Max-Delbrück-Centrum Für Molekulare Medizin Mutagenèse dirigé inductible grâce au sauvetage conditionel d'un gène
CN108707554B (zh) * 2018-05-21 2021-06-29 河北省农林科学院植物保护研究所 一对玉蜀黍黑粉菌组合及其应用
CN115508316B (zh) * 2021-06-23 2025-08-26 山东大学 一种耐药型念珠菌的鉴别方法及鉴别试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016540A1 (fr) * 1995-11-01 1997-05-09 Millennium Pharmaceuticals, Inc. Chitine synthase 1
WO1999031269A2 (fr) * 1997-12-12 1999-06-24 Mcgill University Nouveau candida albicans kre9 et ses utilisations
WO2000053781A1 (fr) * 1999-03-11 2000-09-14 Gpc Biotech, Inc. Generation de mutants de levure conditionnels, techniques et reactifs s'y rapportant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016540A1 (fr) * 1995-11-01 1997-05-09 Millennium Pharmaceuticals, Inc. Chitine synthase 1
WO1999031269A2 (fr) * 1997-12-12 1999-06-24 Mcgill University Nouveau candida albicans kre9 et ses utilisations
WO2000053781A1 (fr) * 1999-03-11 2000-09-14 Gpc Biotech, Inc. Generation de mutants de levure conditionnels, techniques et reactifs s'y rapportant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GARI ELOI ET AL: "A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae", YEAST, CHICHESTER, SUSSEX, GB, vol. 13, no. 9, 1997, pages 837 - 848, XP000926574, ISSN: 0749-503X *
GOW N A R ET AL: "GENES ASSOCIATED WITH DIMORPHISM AND VIRULENCE OF CANDIDA ALBICANS", CANADIAN JOURNAL OF BOTANY, NATIONAL RESEARCH COUNCIL, OTTAWA, CA, vol. 73, no. SUPPL 1, 1995, pages S335 - S342, XP000926595, ISSN: 0008-4026 *
MAO YUXIN ET AL: "Overexpression of a dominant-negative allele of SEC4 inhibits growth and protein secretion in Candida albicans.", JOURNAL OF BACTERIOLOGY, vol. 181, no. 23, December 1999 (1999-12-01), pages 7235 - 7242, XP002180711, ISSN: 0021-9193 *
MENDOZA A ET AL: "Translation elongation factor 2 is encoded by a single essential gene in Candida albicans", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 229, no. 1-2, 18 March 1999 (1999-03-18), pages 183 - 191, XP004161173, ISSN: 0378-1119 *
MIO ET AL: "Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/ FKS1 and its involvement in beta-1,3-glucan synthesis", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 179, no. 13, July 1997 (1997-07-01), pages 4096 - 4105, XP002115088, ISSN: 0021-9193 *
MIO TOSHIYUKI ET AL: "Isolation of the Candida albicans homologs of Saccharomyces cerevisiae KRE6 and SKN1: Expression and physiological function", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 179, no. 7, 1997, pages 2363 - 2372, XP002156281, ISSN: 0021-9193 *

Also Published As

Publication number Publication date
AU2001243204A1 (en) 2001-08-27
EP1292668A2 (fr) 2003-03-19
JP2003523197A (ja) 2003-08-05
NZ521037A (en) 2004-09-24
WO2001060975A2 (fr) 2001-08-23
KR20020097180A (ko) 2002-12-31
CA2398861A1 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
WO2002053728A3 (fr) Procedes de disruption de genes pour identification de cible de medicament
WO2002086090A3 (fr) Identification de genes essentiels d'aspergillus fumigatus, et procedes d'utilisation
WO2004067709A3 (fr) Identification de genes essentiels d'aspergillus fumigatus et methodes d'utilisation
Sun et al. Fungal genome and mating system transitions facilitated by chromosomal translocations involving intercentromeric recombination
Kalman et al. rhlB, a new Escherichia coli K-12 gene with an RNA helicase-like protein sequence motif, one of at least five such possible genes in a prokaryote
WO2001094562A3 (fr) Polymerases d'adn mutantes sensibles au froid
KR20110107846A (ko) 닫힌 선형 ｄｎａ의 제조
EP1655372A3 (fr) Production des polyketides et d'autres produits naturels
WO2003052076A3 (fr) Identification de genes essentiels de cryptococcus neoformans et methodes d'utilisation associees
WO2001060975A3 (fr) Methodologies de disruption genique destinees a la decouverte de medicaments cibles
Clifton et al. Evolutionary repair reveals an unexpected role of the tRNA modification m1G37 in aminoacylation
Lamichhane et al. Plasticity and diversity of tRNA anticodon determinants of substrate recognition by eukaryotic A37 isopentenyltransferases
Zhu et al. Phenotypic, proteomic, and genomic characterization of a putative ABC-transporter permease involved in Listeria monocytogenes biofilm formation
KR101752153B1 (ko) 시프로플록사신 항생제에 대해 내성을 보이는 페스트균 검출을 위한 pna 프로브 및 이의 용도
WO2004056965A3 (fr) Acides nucleiques codant des cibles de medicaments antifongiques et leurs procedes d'utilisation
Lopez-Martinez et al. ATG18 and FAB1 are involved in dehydration stress tolerance in Saccharomyces cerevisiae
Fernández-Ortuño et al. Multiple displacement amplification, a powerful tool for molecular genetic analysis of powdery mildew fungi
Mao et al. ThePhytophthora sojaeGenome Contains Tandem Repeat Sequences Which Vary from Strain to Strain
De Backer et al. Single allele knock-out of Candida albicans CGT1 leads to unexpected resistance to hygromycin B and elevated temperature
KR102159023B1 (ko) Its2 영역을 시퀀싱 하기 위한 증폭용 프라이머 세트 및 이의 용도
Illana et al. Phage φ29 terminal protein residues Asn80 and Tyr82 are recognition elements of the replication origins
US20040121324A1 (en) Barcoded synthetic lethal screening to identify drug targets
Shoji Methylation of 23S rRNA G748 and the ribosomal protein L22 Lys-94 are critical factors for maintaining the association between ribosome stalling and proteome composition in Streptococcus pneumoniae
Garber Prescription RNA
CA2398690A1 (fr) Criblage synthetique letal a <= code barre >= pour identification de cibles de medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2001 560347

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2398861

Country of ref document: CA

Ref document number: 1020027010815

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001916144

Country of ref document: EP

Ref document number: 521037

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001243204

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020027010815

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001916144

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521037

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521037

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001916144

Country of ref document: EP